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Objectives: It has recently been shown that individuals with selective IgA deficiency
(sIgAD) have defective B cell responses both to T cell dependent and independent
mimicking stimulations. The complex intracellular signaling pathways from different
stimuli leading to IgA isotype switching have not been fully elucidated. Thus, the main
objective of this study was to delineate these pathways and their potential role in the
immunopathology linked to sIgAD.
Materials and Methods: PBMCs from 10 individuals with sIgAD and 10 healthy
controls (HC) were activated in vitro via either a T cell dependent or independent
mimicking stimulation. Intracellular phosphorylation of pSTAT3, pSTAT5, pSTAT6, and
as pERK1/2 was evaluated in T and B cells using phosphoflow cytometry.
Results: By evaluating T cell dependent cytokine driven pathways linked to IgA isotype
induction we identified a defect involving an IL-21 driven STAT3 activation isolated to B
cells in sIgAD individuals. However, all other signaling pathways studied were found to
be normal compared to HC. In T cell dependent cytokine driven stimulations linked to
IgA isotype induction the following patterns emerged: (i) IL-10 led to significant STAT3
activation in both T- and B cells; (ii) IL-4 stimulation was predominantly confined to STAT6
activation in both T- and B cells, with some effects on STAT3 activation in T-cells; (iii)
as expected, of tested stimuli, IL-2 alone activated STAT5 and some STAT3 activation
though in both cases only in T-cells; (iv) IL-21 induced significant activation of STAT3
in both T- and B cells, with some effects on STAT5 activation in T-cells; and finally (v)
synergistic effects were noted of IL-4+IL-10 on STAT5 activation in T-cells, and possibly
STAT6 in both T- and B cells. On the other hand, CPG induced T cell independent
activation was confined to ERK1/2 activation in B cells.
Conclusion: Our results indicate a diminished STAT3 phosphorylation following IL-21
stimulation solely in B cells from sIgAD individuals. This can represent aberrant germinal
center reactions or developmental halt. Thus, our work provides further insight into the
unraveling of the previously hypothesized role of IL-21 to reconstitute immunoglobulin
production in primary antibody deficiencies.
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INTRODUCTION
Selective IgA deficiency (sIgAD) is the most common primary
antibody deficiency (PAD) in Caucasians characterized by an
increased risk of autoimmunity, atopic diseases, and infections
(1). It is defined as serum IgA ≤ 0.07 g/L with normal
serum levels of IgG and IgM (2). In the normal host
multiple factors are known to be needed for a correct B cell
maturation to IgA secretion. These include the use of correct
genetic information, transcription of key molecules and complex
intracellular signaling pathways (3). Even though genes encoding
for IgA have not been shown to be abnormal in sIgAD its
production remains defective (4). Aberrations are seen in early
maturing B cell lineages (5–7) and the defect has been corrected
through stem cell transplant by correcting a defect in B cell
ontogeny (8). B cells from sIgAD individuals have been shown
to be able to produce little amounts of IgA after various T cell
dependent and independent mimicking in vitro stimulations.
Most commonly this includes CD40L with TGF-ß1, IL-2, IL-
4, IL-10, and IL-21 at various concentrations and combinations
(5, 6, 9–12). However, despite successful IgA secretion in these
T-cell dependent stimulatory conditions, they have not been able
to rectify IgA levels up to normal compared to healthy controls
(5, 6, 9–12). Some have hypothesized that this could be used in the
treatment of hypogammaglobulinemia but the problem is that
such stimulation has been shown to lead to faulty longevity (7).
TLR9 is known to be a strong inducer of IgA secretion in healthy
individuals but were recently shown to be defective in sIgAD
(7). Given the importance of TLR9 at mucosal surfaces and its
potential defect in sIgAD, studying this receptor might provide
new insights in its connection to IgA secretion and mucosal
immunology (7).
JAK-STAT signaling is known to be essential in the
intracellular transduction following activation of cells by
common gamma chain cytokines, IL-2, IL-4, IL-7, IL-9, IL-
15, and IL-21; all known to affect class switching to IgA,
and its subsequent production by B cells (13). Of these IL-
21 has been of special interest and often theorized as having
the strongest therapeutic potential in sIgAD (3, 5). Interestingly
while many of the common gamma chain cytokines are
known to have impaired IgA inducing capacities in sIgAD
they have been shown to use similar intracellular signaling
cascades (14). Complete gain of function and loss of function
in the JAK-STAT pathways have been shown to lead to severe
phenotypes with lymphocyte affections (15). Possibly a slighter
defect or partial affection may lead to different phenotypes
and makes it essential to further elucidate them and their
potential role in this disease. Especially since the cytokines
known to be defective in sIgAD are described as using similar
Abbreviations: CD40L, CD40 ligand, alternatively CD154; CVID, Common
variable immunodeficiency; ERK, Extracellular regulated kinases; GMFI,
Geometric mean of fluorescence intensity; HCs, Healthy controls; Ig,
Immunoglobulin; IL, Interleukin; JAK, Janus kinase; PAD, Primary antibody
deficiency; PBMC, Peripheral blood mononuclear cell; PBS, Phosphate buffer
saline; RPM, Rotation per minute; sIgAD, Selective immunoglobulin A deficiency;
STAT, Signal transducer and activator of transcription; Tfh, T follicular helper cell;
TGF- β, Transforming growth factor β; TLRs, Toll-like receptors.
signaling cascades. But to do so one needs to assess the
reactivity of specific populations to stimuli it is not always well-
defined how these may affect different pathways in different
cell subgroups.
The development of novel biological targets in signaling
pathways for the treatment of various diseases related to immune
modulation (16) has awoken an interest in phosphorylation
defects in immune mediated diseases (17). Signaling defects
have furthermore been described in similar PIDs to sIgAD,
like common variable immune deficiency (CVID), where a
concomitant risk for the development of autoimmunity is known
(18). CVID individuals have been shown to have both a CpG-
driven STAT3 (19) and a CD40L and αIgM driven p-AKT B cell
defects (18).
Thus, it is important to understand the intracellular
responsiveness of cytokines inducing IgA production and
evaluate the responses in sIgAD B- and T cells. That way it
may be possible to elucidate if the defects in IgA production are
related to altered signaling as in CVID. The main objective of
this study was therefore to investigate intracellular pathways in
B and T cells of sIgAD individuals and healthy controls (HCs)
by examining phosphorylation responses using multicolor flow
cytometric phosphoflow analysis.
MATERIALS AND METHODS
sIgAD Patients and Healthy Donors
Peripheral blood from 10 individuals from the Icelandic sIgAD
cohort (1) were collected into heparinized tubes after obtaining
informed consent (in accordance with procedures approved by
The National Bioethics Committee and The Data Protection
Authority in Iceland). These were compared to gender matched
healthy controls from the blood bank. None of the patients
had ongoing acute infection at the time of sample collection
or were receiving immunosuppressive therapy. The adult sIgAD
diagnosis was based on the criteria from ESID Registry, which
is an individual over 17 years of age with a serum IgA
of <7 mg/dl (0.07 g/L) but normal serum IgG and IgM,
in whom other causes of hypogammaglobinaemia had been
excluded (2, 20).
Isolation of Peripheral Blood
Mononuclear Cells
Peripheral Blood Mononuclear cells (PBMCs) were
isolated from heparinized peripheral blood using
Ficoll–Paque gradient centrifugation (Sigma-Aldrich, St.
Louis, MO, USA).
Sample Freezing and Storage
After isolation the cells were suspended in X-vivo 20 serum free
medium (Lonza; Walkersville, Maryland, USA). Cells frozen in
X-vivo were supplemented with ProFreeze chemically defined
freezemedium (Lonza; Verviers, Belgium). Cell suspensions were
mixed with DMSO (Sigma Aldrich) to prevent damage and then
cryopreserved in liquid nitrogen.
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Phospho Protein Staining for Validation
of Protocol
A phosphoflow stimulation and staining protocol was established
and optimized which was based onmethods previously published
(21, 22). Briefly; cryotubes were taken out of liquid nitrogen
storage and thawed quickly in a 37◦C water bath. They were
then gently pipetted using Pasteur pipettes into 50ml conical tube
containing 25ml of IMDMmedium. Cells were then centrifuged
at room temperature at 300xg for 10min and the supernatant
discarded. Washing was repeated with 25ml of IMDM medium
and the cell pellet was re-suspended in medium and counted.
5 × 105 cells per well were aliquoted into sterile 96 well
plates (#163320 Thermo fisher, Waltham, Massachusetts, USA).
The cells were then incubated for 1 h at 37◦C in a 5% CO2
incubator to let the cells reach a basal phosphorylation. Cells
were stimulated with various concentrations and combinations of
cytokines for 15min at 37◦C and then fixed in 1.8% formaldehyde
for 10min at room temperature. Cells were then pelleted and
centrifuged at 1600 RPM at 4◦C for 10min. Supernatants were
then discarded, and cells washed with 200 µl of staining buffer.
Cells were then permeabilized with 150 µl of ice-cold 95%
methanol. This was followed by washes, first with 80 µl of
staining buffer and then repeated with 200 µl of staining buffer.
Cell pellet was re-suspended in the residual volume and 50 µl
of that was transferred to fresh 96-well plate. Staining with fluor
conjugated antibodies was carried out in the dark for 30min
at room temperature. One more wash was performed with 100
µl of staining buffer and then the samples were put on ice
until analysis with Beckman Coulter Navios flow cytometer. For
each analysis a minimum of 50.000 events were collected into
a defined lymphocyte gate. Antibodies used were Alexa flour
488 anti-human ERK1/2 (T202/Y204) (#53-9109-42 Ebioscience,
Vienna, Austria), PE anti-human pSTAT1(Y701) (#12-9008-42
Ebioscience), APC anti-human pSTAT3 (Y705) (#17-9033-42
Ebioscience), PE-Cyanine 7 anti-human pSTAT5 (Y694) (#25-
9010-42 Ebioscience), Pacific Blue anti-human p38 (T180/Y182)
(#560313 BD biosciences, San Jose California, USA), PerCp Cy
5.5 anti human CD20 clone H1 cytoplasmic tail (#55802 1 BD
biosciences), Brilliant violet 510 anti-human CD3 (clone UCHT1
# 300448 Biolegend, San Diego California, USA). Stimulations
used were IL-2 (50 ng/ml), IL4 (100 ng/ml), IL-10 (100 ng/ml),
IL-21(50 ng/ml) (all from R&D systems, Minneapolis Minnesota,
USA), and CpG-ODN2006 (1µg/ml TLR9 agonist, InvivoGen,
San Diego California, USA).
FIGURE 1 | Differences in percentage of pSTAT3, pSTAT5, pSTAT6, and ERK1/2 expression in T and B cells in healthy controls. The figure shows the % of expression
of pSTAT3 (S1A), pSTAT5 (S1B), pSTAT6 (S1C), and ERK1/2 (S1D) as measured ex vivo in PBMCs after 15min stimulation of IL-2 (50 ng/ml), IL4 (100 ng/ml), IL-10
(100 ng/ml), IL-21 (50 ng/ml), or CpG ODN 2006 (1µg/ml TLR9 agonist) alone or in combinations in CD3 + T and CD20 + B cells of healthy individuals. (A) shows the
percentage of pSTAT3 positive T (CD3+) and B cells (CD20+). A positive response is seen with IL-10, IL-10 + IL-2, IL-10 + IL-4, and IL-21 stimulation but none after
IL-2, IL-4 alone, or CpG. (B) shows the percentage of pSTAT5 positive T (CD3+) and B cells (CD20+). A positive response is seen with IL-2, IL-10 + IL-2, and IL-10 +
IL-4 in T cells but IL-10 + IL-2 in B cells, but no activation in neither T nor B cells after IL-4, IL-10, IL-21, or CpG. (C) shows the percentage of pSTAT6 positive T
(CD3+) and B cells (CD20+). A positive response is seen with IL-4 and IL-10 + IL-4 in T and B cells, but no activation in neither T nor B cells after IL-2, IL-10, IL-10 +
IL-2, IL-21, or CpG. (D) shows the percentage of ERK1/2 positive T (CD3+) and B cells (CD20+). A positive response is seen with CpG stimulation in B cells but not
in T cells. Furthermore, no activation is seen in either T nor B cells after IL-2, IL+4, IL-10, IL-10 + IL-2, IL-10 + IL-4, IL-21, or CpG. Significance was calculated in
relation to the control group. ***p < 0.001, ****p < 0.0001 (as determined by one-way ANOVA).
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Flow Cytometric Analysis
Flow cytometric data was analyzed with Kaluza version 1.3.
Sample analysis was performed in a blinded manner, which
is to say that the researcher could not know which group a
sample belonged to until after the analysis was complete. When
testing activation induced phosphorylation, results are displayed
as fold change of the GMFI (geometric mean of fluorescence
intensity) value of the stimulated vs. unstimulated sample.
Examples of phosphorylation and gating strategies to be seen in
Supplement Figures 2,3.
Data Presentation and Statistical Analysis
Graphical data presentation and Statistical analysis was
performed with Graph Pad Prism version 8.0.1. To test for
normal distribution of data Shapiro-Wilk test was performed.
Datasets did not all pass normality tests and therefore
Kruskal–Wallis 1-way ANOVA was performed on datasets
with Dunn’s post-test.
RESULTS
Mapping of T-Cell Dependent and
Independent Intracellular Phosphorylation
of STAT3, STAT5, STAT6, and ERK1/2
Related to IgA Induction Reveals a
Complex and Heterogeneous
Phosphorylation Pattern
Lymphocytes from HCs demonstrate a variable pattern of
pSTAT3, pSTAT5, pSTAT6, and ERK1/2 depending on the given
underlying stimulatory conditions (Figure 1). In our model it
was important to assess the stimulations previously shown in
the literature to be defective in sIgAD, that is IL-2, IL-4, IL-
10, IL-21, and CpG. Furthermore, it was important to try the
concomitant stimulation of IL-10 and either IL-2 and/or IL-4
since it has been shown that these improve IgA secretion in
sIgAD (10). In exploring the responses of these above-mentioned
stimuli in pSTAT3 expression a good response was seen after
FIGURE 2 | The percentage and fold change GMFI of pSTAT3 in B (CD20+) and T cells (CD3+) after IL-21 and IL-10 in sIgAD individuals and healthy controls. The
figure shows % of phosphorylated and fold change GMFI of STAT3 as measured ex vivo in PBMCs after 15min stimulation of IL-21 (50 ng/ml), IL-10 (100 ng/ml) + IL4
(100 ng/ml) and IL-2 (50 ng/ml). Analysis of (A) % pSTAT3 positive B cells (CD20+) and (B) fold change GMFI shows a significant lower percentage of B cells
expressing pSTAT3 after IL-21 stimulation but no differences between phosphorylation responses after IL10 in sIgAD and HCs. Analysis of (C) % pSTAT3 positive T
cells (CD3+) and (D) fold change GMFI shows no differences between phosphorylation responses after IL-21 and in sIgAD compared to HCs. Significance was
calculated in relation to the control group. *p < 0.05, **p < 0.01, ****p < 0.0001 (as determined by one-way ANOVA).
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FIGURE 3 | The percentage and fold change GMFI of pSTAT5 in B (CD20+) and T cells (CD3+) after IL-21, IL-10 + IL4, and IL-2 in sIgAD individuals and healthy
controls. The figure shows % of phosphorylated and fold change GMFI of STAT5 as measured ex vivo in PBMCs after 15min stimulation of IL-21 (50 ng/ml), IL-10
(100 ng/ml) + IL4 (100 ng/ml), and IL-2 (50 ng/ml). Analysis of (A) % pSTAT5 positive B cells (CD20+) and (B) fold change GMFI shows a no significant difference in
the percentage or fold change GMFI of B cells expressing pSTAT5 after IL-21, IL-10 + IL4, and IL-2 stimulation in sIgAD and HCs. Analysis of (C) % pSTAT5 positive T
cells (CD3+) and (D) fold change GMFI shows neither differences between phosphorylation responses in T cells after IL-21, IL-10 + IL4, and IL-2 stimulation in sIgAD
and HCs. Significance was calculated in relation to the control group. *p < 0.05, ****p < 0.0001 (as determined by one-way ANOVA).
IL-10 and IL-21 separately in both T and B cells (Figure 1A).
However, neither antagonistic nor synergistic effects were found
in any of the conditions tested (Figures 1A, 2A,C). The mapping
of STAT5 signaling following various T-cell dependent and
independent mimicking stimulations revealed that significant
phosphorylation was confined to T-cells. Of the stimulations
tested, IL-2 alone induced phosphorylation in T cells. Dual
stimulation with IL-2 and IL-10 induced phosphorylation in
both T- and B cells. Dual stimulation with IL-4 and IL-10
did also induce significant STAT5 phosphorylation in T cells
but not B cells while alone neither IL-4 nor IL-10 alone did
induce significant STAT5 phosphorylation in B cells. Regarding
pSTAT6 expression, expression was seen after IL-4 stimulation
in both T- and B cells (Figure 1C). For T cell independent
responses, the evaluation ERK1/2 expression was done following
CPG stimulation and where expression was seen following
stimulation in a small proportion of B cells in both HCs
and IgAD (Figure 5A, HC B cells 17.7% +/– 1.0 vs. sIgAD
B cells 13.8%+/– 2.6).
IL-21 Driven Phosphorylation of STAT3 Is
Lower in sIgAD B Cells Compared to HCs
Since when exploring pSTAT3 expression after various stimuli
a good response was seen after IL-10 and IL-21 separately
(Figure 1A) these where tested in sIgAD. Proportionally fewer B
cells responded to IL-21 driven STAT3 phosphorylation in sIgAD
compared to HCs (Fraction of HC B cells = 30.4% +/−11.5
vs. sIgAD B cells 16.1% +/– 7.5; p = 0.03; Figures 2A,C)
but not in GMFI fold change (HC B cells = 2.3+/−0.3
vs. sIgAD B cells = 1.6 +/– 0.3; p < 0.14; Figures 2B,D).
In addition, when evaluating non-fold change adjusted
GMFI for the pSTAT3 activation the sIgAD demonstrated
a lower response (HC vs. sIgAD pSTAT3 GMFI 4.74 vs.
3.61; p = 0.032), and the fold GMFI change difference
tended also to be lower for the sIgAD group compared to
HCs (HC vs. sIgAD pSTAT3 fold change GMFI 2.26 vs.
1.60; p= 0.098).
STAT5 Phosphorylation Is Seen in After
IL-2 and Concomitant IL-4 With IL-10
Stimulation
STAT5 signaling in healthy controls revealed that significant
phosphorylation after IL-2 stimulation was confined to T-cells
(Figure 1B). In sIgAD it has been shown that the addition of
IL-2 to IL-10 stimulation leads to higher “rescue production”
of IgA after stimulation compared to IL-10 alone (10). In our
setup a difference was seen in percentage of phosphorylation
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FIGURE 4 | The percentage and fold change GMFI of pSTAT6 in B (CD20+) and T cells (CD3+) after IL-4 and IL-10 + IL4 in sIgAD individuals and healthy controls.
The figure shows % of phosphorylated and fold change GMFI of STAT6 as measured ex vivo in PBMCs after 15-minute stimulation of IL-4 (100 ng/ml) and IL-10
(100 ng/ml) + IL4 (100 ng/ml). Analysis of (A) % pSTAT6 positive B cells (CD20+) and (B) fold change GMFI shows a no significant difference in the percentage or fold
change GMFI of B cells expressing pSTAT6 after IL-4 or IL-10 + IL4 stimulation in sIgAD and HCs. Analysis of (C) % pSTAT6 positive T cells (CD3+) and (D) fold
change GMFI shows neither differences between phosphorylation responses in T cells after IL-4 or IL-10 + IL4 stimulation in sIgAD and HCs. Significance was
calculated in relation to the control group. *p < 0.05, ****p < 0.0001 (as determined by one-way ANOVA).
in STAT5 in B cells with IL-21, IL-10 + IL-4, or IL-2 alone
for HCs (Figure 1B). When analyzing these stimulations in
sIgAD compared to HCs we did not observe any differences
between the two groups in cell proportions or fold change
GMFI (Figures 3A–D) following IL-21, dual IL-10 with IL-4 or
IL-2 stimulation.
Only IL-4 Induces a Significant STAT6
Phosphorylation in Both T- and B Cells
pSTAT6 expression was only seen after IL-4 stimulation in both
T- and B cells, with slight but noticeable synergistic effects
following dual IL-4 and IL-10 stimulations in B cells only
(Figure 1C). No differences where seen in the fraction nor fold
change GMFI between the two cohorts after IL-4 or IL-4+ IL-10
stimulation (Figures 4A–D).
Minimal ERK Activation in B Cells
Following CpG Stimulation
Since expression of ERK1/2 was only seen following
T-cell independent stimulation in HCs and since its
basal phosphorylation of ERK1/2 without stimulation
(Supplement Figures 1A,B) did not differ significantly between
T or B cells in both groups, sIgAD and HCs, it was hypothesized
that some differences could be seen in sIgAD since stimulation
with CpG leads to defective IgA production in sIgAD. No
differences where seen in ERK1/2 expression in sIgAD compared
to HCs in our model in T or B cells (Figures 5A,B).
IL-21 Driven STAT3 Phosphorylation Is
Diminished in sIgAD B Cells
Since STAT3 phosphorylation was highly upregulated following
both IL-10 and IL-21 separately it was important to evaluate their
role in sIgAD (Figure 2). Interestingly, as shown in Figure 2A,
significantly fewer B cells were capable of phosphorylating STAT3
in response to IL-21 in sIgAD compared to HC, whereas IL-
10 induced STAT3 activation was normal in sIgAD B cells
(Figure 2A). However, such an IL-21 driven STAT3 activation
defect was not found in sIgAD T-cells. As depicted in Figure 6, in
a visual manner, this defect was only seen for STAT3 but not all
the other T-cell dependent and T-cell independent intracellular
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FIGURE 5 | Effects of CpG on ERK1/2 expression in B and T cells from sIgAD individuals and healthy controls. The figure shows the % of expression and fold change
GMFI of ERK1/2 as measured ex vivo in PBMCs after 15min stimulation of CpG ODN 2006 (1µg/ml TLR9 agonist). Analysis of (A) % ERK1/2 positive B cells
(CD20+) and (B) fold change GMFI shows a no significant difference in the percentage or fold change GMFI of B cells expressing ERK1/2 after CpG stimulation in
sIgAD and HCs. Analysis of (C) % CpG positive T cells (CD3+) and (D) fold change GMFI shows neither differences between phosphorylation responses in T cells
after CpG stimulation in sIgAD and HCs. Significance was calculated in relation to the control group. ***p < 0.001 (as determined by one-way ANOVA).
signaling pathways linked to IgA induction tested (Figures 3–
5). The figure depicts the hypothesized model of sIgAD at the
mucosal surface. The size of the B cell is exaggerated to draw forth
the intracellular focus of the paper.
DISCUSSIONS
In this study, we identify defective STAT3 phosphorylation
responses to IL-21 in sIgAD B cells. We were able to do so
after mapping out the complex and heterogeneous intracellular
signaling cascades following various stimuli known to be
important in IgA induction. We both look at T-cell dependent
cytokines and T-cell independent TLR9 responses. Delineating
the intracellular signaling pathways under T- cell dependent
and independent stimulatory conditions linked to IgA induction
revealed that IgA induction in B cells may be driven through
various pathways. Both IL-21 and IL-10 have had a strong link
to sIgAD (5), and it was of special interest that both induced the
strongest STAT3 phosphorylation of tested stimuli. But looking
at sIgAD individuals we only identified a defect in IL-21 driven
STAT3 phosphorylation. This potential defect may have several
underlying causes. The defect may be linked to some narrowly
defined effector B cell sub-population, since recently we have for
example identified a defect involving transitional B cells in sIgAD
(7). But the defect may also reflect a secondary dysregulation due
to abnormal reactions in IgAD to heterogeneous stimulations,
with common gamma chain cytokines, IL-10 or TRL9, needed
for a correct IgA class switching (5, 6, 9–12).
IL-21 has been claimed to be the most promising curative
target in sIgAD (3). A role that could be supported by our
observations. The differences in responsiveness seen in sIgAD
could be hypothesized to be downstream of the IL21 receptor
but the normal responses seen with other stimuli make this
highly unlikely. We rather see a cytokine specific response
pattern for IL-21 (7), highlighting the potential role for IL-
21 in antibody deficiencies. In addition, given the normal
response to all IL-10 driven down-stream signaling events in
our study it is not surprising that IL-10 is not capable to
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FIGURE 6 | A schematic figure showing the intracellular phosphorylation responses in healthy individuals of STAT3, STAT5, STAT6, and ERK1/2 expression after
stimulation with IL-2, IL4, IL-10 ± IL-2 or IL-4, IL-21, and CpG based on the results from Supplement Figure 1. The figure shows a visual representation of a B cell in
IgAD and the different stimuli tested, differences are seen in activation based on stimuli. The Stimuli leading to activation are shown with an arrow with an unbroken
line (→ ) and the potential signal leading to intranuclear translation with an arrow with a broken line (- - → ). STAT3 phosphorylation is seen after IL-10 and IL-21
stimulation. STAT5 phosphorylation is seen after IL-2 and IL-4 with IL-10 stimulation but with neither alone. STAT6 phosphorylation is seen after IL-4 stimulation.
ERK1/2 expression is seen after TLR9 activation. A defect is seen in sIgAD in B cells in pSTAT3 after IL-21 stimulation.
normalize IgA production in sIgAD (7). IL-21 is furthermore
the cytokine that is most strongly linked with germinal center
maturation where class switched B cells emerge, which have
recently been shown to be abrogated in numbers and percentage
in sIgAD (7). While IL-21 is known to be secreted by T
follicular helper cells (TFh) in germinal center reactions, this
lymphocytic sub-population does not seem to be the culprit in
the pathogenesis of sIgAD since these are normal in number
and function in sIgAD (7). However, it is conceivable that a
subtler defect might exist in in vivo germinal center settings
not detected in our model. This could also be linked to TLR9
defects seen prior (7) since the co-stimulation of CpG and IL-
21 has been shown to enhance the STAT3 phosphorylation in
humn B cells (23).
The heterogeneity in responses of sIgAD B cells to
common gamma chain cytokines has been of interest given
their overlapping signaling pathways (14). Common gamma
chain cytokines have in common that their respective cell
surface receptors all contain the common gamma amino
acid chain (CD132) and they utilize intracellular signaling
in similar ways. The main signaling pathway responsible in
relaying signals of these cytokines is the JAK/STAT signaling
pathway (13). JAK proteins phosphorylate different STAT
proteins which then affect transcription of target genes (5,
9, 10, 12). The heterogeneous signaling responses seen in
this study do though underline differences in the function
of these cytokines. Furthermore, in healthy individuals a
novel synergetic effect was noted for IL-4 and IL-10 on
STAT5 phosphorylation in T-cells and B cells pointing toward
multiple stimuli scenarios leading to different modulations.
These responses did not occur when the cytokines were used
separately. Something that could be affecting the fine tuning
through multiple inhibitor approaches in clinical settings. The
results do furthermore reflect on the importance of analyzing
complex arrays of intracellular signaling events in various
sub-populations of lymphocytes. Whereas, through several
simultaneous intracellular pathways, phosphoflow offers the
addition of getting a pattern of many pathways at once for
separate cell populations with minimal chance of affecting
activation status of cells via isolation.
The fact that a signaling defect is only seen after T cell
dependent but not T cells independent mimicking stimulations
is of interest given the stronger induction of IgA after CpG
than T cell dependent stimulation in both the HCs and sIgAD
cohorts (7). Thus, in another and related PAD, CVID, a defect
has recently been shown after TLR9 stimulation in STAT3
signalization (19). Even though our observations described here
do not demonstrate a defect involving the TLR9 driven signaling
pathway, it was interesting that a defect involving STAT3
activation is shared for both conditions. However, in our model
no meaningful STAT3 signaling was noted following CPG-TLR9
driven activation, even in HCs. In addition, TLR9 activation
has been predominantly linked to the IRAK4, MYD88, and
ERK, supported by our findings and described here in defined
lymphocyte sub-populations (24).
The limitations of the study like with all studies estimating
intracellular phosphorylation proteins are the phospho epitopes
stained for. Even though the phosphorylation sites on tyrosine
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fragments stained for are the primary site for signal transduction
other phosphorylation patterns do exist, for example serine
phosphorylation of STATs (25). With regard to the activation
of B cells in sIgAD it could be argued that the phosphorylation
of plasma blasts in the periphery is not detected, because
of their paucity and low expression of CD20, but since
it has been recently shown that these are not present in
peripheral blood of sIgAD individuals (7) and may not be
most sensitive to the chosen stimuli targeting naïve and
memory B cells. To fully elucidate the potential involvement
of other lymphocytic sub-populations confined to the primary
and/or secondary lymphoid organs a more detailed analyzes
on these organs would be needed. However, these were
not accessible to us at the time of the study due to
ethical considerations.
It could be argued that basal phosphorylation could influence
the analysis of differences between deficient and non-deficient
individuals. Especially since it has been shown that the
constitutive (basal) levels of phosphorylated kinases can vary in
various pathological states we compared the phosphorylation of
unstimulated samples in sIgAD compared to HCs (22). However,
no noticeable difference was found between the two groups when
evaluating basal phosphorylation state for any of the intracellular
pathways evaluated in both HC and sIgAD in our study.
The above findings further strengthen a potential role
for IL-21 as a therapeutic target in sIgAD, that could be
monitorable through intracellular signaling events of STAT3
(5). Further research is needed though before administrating
IL-21 or other cytokines to sIgAD individuals to revert the
defect since special care should be taken with regards to
defects in longevity of plasma cells in IgAD (7), as the amount
of autoantibodies (26–28) and their potential inducibility in
PADs could be enhanced with such exogenous stimuli (29).
Whereas, the cytokine abrogating effects of biologicals and
novel JAK/STAT inhibitors might have a role in the treatment
of sIgAD or other hypogammaglobinaemia’s with concomitant
autoimmunity. This might be especially true in circumstances
with sIgAD in connection to severe forms of atopic and/or
autoimmune manifestations given their potential and emerging
heterogeneous functional clinical responses (30).
In conclusion, our findings clarify the pathways activated by
different stimuli linked to IgA induction. They furthermore shed
light on the prior hypothesized immunotherapeutic role of IL-21
to revert the paucity in immunoglobulin subtype production in
PADs by describing a defect in B cell phosphorylation after IL-21
in pSTAT3 in IgAD. Further research is still needed to develop a
therapeutic approach based on these results in sIgAD and other
related diseases.
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Supplement Figure 1 | Basal phosphorylation in B and T cells from sIgAD and
HCs. The figure shows % of phosphorylated proteins as measured ex vivo in
PBMCs. (A) B cells (CD20+) and (B) T cells have a similar basal phosphorylation
of STAT3, STAT5, STAT6, and expression of ERK1/2 in sIgAD individuals
compared to HCs. The variation does not differ between measured proteins other
that pSTAT3 in T cells (Figure 1B). Significance was calculated in relation to the
control group.
Supplement Figure 2 | Validation of staining for STAT1, STAT3, STAT5, STAT6
signaling pathways. PBMCs were isolated from a healthy individual then either left
unstimulated or stimulated with IFN-γ, IL-21, IL-2, or IL-4 for 15min then fixed,
permeabilized and stained for phosphorylated STAT1, STAT3, STAT5, STAT6 then
analyzed with flow cytometer. Orange is a negative control sample unstained and
unstimulated, blue is an isotype control sample stimulated, green is stained
sample unstimulated, and gray is stained sample stimulated. Lymphocytes are
displayed on the left and monocytes on the right.
Supplement Figure 3 | Gating strategy for experiments. (A) Gating on single cells
and CD3/CD20 positive cells. (B) gating of STAT1 in stimulation giving positive
stimulation: IL-10, IL-10 + IL2, IL-10 + IL4, and IL-21 stimulation. Staining of an
sIgAD individuals with IL-21 is shown in the box marked sIgAD. (C) Staining of
pSTAT5 after IL-10, IL-10 + IL2, IL-10 + IL4 stimulation. (D) Stating of pSTAT6
after IL-4 and IL-10 + IL4 stimulation. (E) Staining of ERK after CpG stimulation.
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